More than 50 HIV-1-infected patients, naive of antiretroviral therapy (ART) but eligible for first line ART in JJ Hospital, Mumbai, India were investigated for surveillance drug resistance mutations (SDRMs); all but one virus belonged to subtype C; we could observe SDRMs to nonnucleoside reverse transcriptase inhibitors and protease inhibitors in 9.6% of the patients.
Get full access to this article
View all access options for this article.
References
1.
WensingAM, van de VijverDA, AngaranoG, AsjöB, BalottaC, BoeriE, CamachoR, ChaixML, CostagliolaD, De LucaA, DerdelinckxI, GrossmanZ, HamoudaO, HatzakisA, HemmerR, HoepelmanA, HorbanA, KornK, KüchererC, LeitnerT, LovedayC, MacRaeE, MaljkovicI, de MendozaC, MeyerL, NielsenC, Op de CoulEL, OrmaasenV, ParaskevisD, PerrinL, Puchhammer-StöcklE, RuizL, SalminenM, SchmitJC, SchneiderF, SchuurmanR, SorianoV, StanczakG, StanojevicM, VandammeAM, Van LaethemK, ViolinM, WilbeK, YerlyS, ZazziM, BoucherCA. SPREAD Programme: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis, 2005; 192:958–966.
2.
ChanPA, KantorR. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther, 2009; 3:447–465.
3.
JordanMR, BennettDE, BertagnolioS, GilksCF, SutherlandD. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther, 2008; 13,Suppl 2:15–23.
4.
BennettDE, CamachoRJ, OteleaD, KuritzkesDR, FleuryH, KiuchiM, HeneineW, KantorR, JordanMR, SchapiroJM, VandammeAM, SandstromP, BoucherCA, van de VijverD, RheeSY, LiuTF, PillayD, ShaferRW. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE, 2009; e4724.
5.
BennettDE, BertagnolioS, SutherlandD, GilksCF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther, 2008; 13,Suppl 2:1–13.
6.
ChaturbhujDN, HingankarNK, SrikantiahP, GargR, KabraS, DeshmukhPS, JadhavSD, ThoratSR, DatkarSR, MehtaP, IngoleN, MathurM, RamachandranA, HaldarP, ReddyDC, BachaniD, RaoS, TripathySP, ParanjapeRS. Transmitted HIV drug resistance among HIV-infected voluntary counseling and testing centers (VCTC) clients in Mumbai, India. AIDS Res Hum Retroviruses, 2010; 26:927–932.
7.
DeshpandeA, JeannotAC, SchriveMH, WittkopL, PinsonP, FleuryHJ. Analysis of RT sequences of subtype C HIV-type 1 isolates from Indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines. AIDS Res Hum Retroviruses, 2010; 26:343–350.
8.
AroraSK, GuptaS, ToorJS, SinglaA. Drug resistance-associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India. AIDS Res Hum Retroviruses, 2008; 24:125–130.
9.
IqbalHS, SolomonSS, MadhavanV, SolomonS, BalakrishnanP. Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India. J Int Assoc Physicians AIDS Care (Chic), 2009; 8:323–327.
10.
LallM, GuptaRM, SenS, KapilaK, TripathySP, ParanjapeRS. Profile of primary resistance in HIV-1-infected treatment-naive individuals from Western India. AIDS Res Hum Retroviruses, 2008; 24:987–990.
11.
BarthRE, van der LoeffMF, SchuurmanR, HoepelmanAI, WensingAM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: A systematic review. Lancet Infect Dis, 2010; 10:155–166.
12.
SmithDM, WongJK, ShaoH, HightowerGK, MaiSH, MorenoJM, IgnacioCC, FrostSD, RichmanDD, LittleSJ. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: Implications for secondary transmission. J Infect Dis, 2007; 196:356–360.
